{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T16:18:12Z","timestamp":1780935492123,"version":"3.54.1"},"reference-count":0,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[1978,2,1]],"date-time":"1978-02-01T00:00:00Z","timestamp":255139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1978,2]]},"abstract":"<jats:p>The pharmacokinetics of amphotericin B were studied in two patients at the conclusion of long-term therapy for disseminated histoplasmosis. The distribution kinetics of this drug were adequately described by a three-compartment mamillary model with a total distribution volume averaging 4 liters\/kg. The elimination phase half-life of amphotericin B was approximately 15 days, reflecting slow release of amphotericin B from a peripheral compartment. In accordance with previous reports, renal excretion accounted for only 3% of total amphotericin B elimination. The pharmacokinetic model for one of the patients also was used to compare the simulated amphotericin B serum levels that would be expected if initial therapy followed two recommended regimens.<\/jats:p>","DOI":"10.1128\/aac.13.2.271","type":"journal-article","created":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T23:57:02Z","timestamp":1340841422000},"page":"271-276","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":199,"title":["Amphotericin B Pharmacokinetics in Humans"],"prefix":"10.1128","volume":"13","author":[{"suffix":"Jr.","given":"Arthur J.","family":"Atkinson","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Center, Departments of Medicine and Pharmacology, Northwestern University Medical School, Chicago, Illinois 60611,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Bennett","sequence":"additional","affiliation":[{"name":"Clinical Myocology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20014"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.13.2.271","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.13.2.271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:15:05Z","timestamp":1645485305000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.13.2.271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1978,2]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1978,2]]}},"alternative-id":["10.1128\/AAC.13.2.271"],"URL":"https:\/\/doi.org\/10.1128\/aac.13.2.271","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1978,2]]},"assertion":[{"value":"1978-02-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}